Patents by Inventor Paul Mathias
Paul Mathias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240093318Abstract: Provided by the inventive concept is a DNA methylation-based platform, and machine learning algorithms, for diagnosing respiratory pathogens including SARS-CoV-2 and predicting COVID-19 related outcomes, and methods of using the same, such as in identifying the presence of a viral infection, such as a SARS-CoV-2 infection, determining whether a subject has COVID-19, and/or whether a subject with COVID-19 is likely to develop acute respiratory distress syndrome or multisystem inflammatory syndrome in children.Type: ApplicationFiled: June 23, 2021Publication date: March 21, 2024Inventors: KATHLEEN BARNES, IVANA YANG, CHRISTOPHER GIGNOUX, RASIKA MATHIAS, PAUL NORMAN, ALEM TAYE, RISHI PORECHA, BRET BARNES, BRETT PETERSON
-
Publication number: 20230339960Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.Type: ApplicationFiled: June 28, 2023Publication date: October 26, 2023Inventors: JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
-
Publication number: 20230250100Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: April 13, 2023Publication date: August 10, 2023Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Gavrin, Ivan Viktorovich Efremov
-
Patent number: 11702424Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: August 18, 2020Date of Patent: July 18, 2023Assignee: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Publication number: 20210171534Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: February 18, 2021Publication date: June 10, 2021Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Gavrin, Ivan Viktorovich Efremov
-
Publication number: 20200377511Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: August 18, 2020Publication date: December 3, 2020Applicant: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Patent number: 10793579Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: May 14, 2019Date of Patent: October 6, 2020Assignee: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Patent number: 10766904Abstract: The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: GrantFiled: July 9, 2019Date of Patent: September 8, 2020Assignee: Cystic Fibrosis FoundationInventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Ivan Viktorovich Efremov
-
Publication number: 20200017512Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: September 20, 2019Publication date: January 16, 2020Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Gavrin, Ivan Viktorovich Efremov
-
Patent number: 10494374Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: GrantFiled: April 5, 2019Date of Patent: December 3, 2019Assignee: CYSTIC FIBROSIS FOUNDATIONInventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Gavrin, Ivan Viktorovich Efremov
-
Publication number: 20190330219Abstract: The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: July 9, 2019Publication date: October 31, 2019Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Ivan Viktorovich Efremov
-
Publication number: 20190303861Abstract: Various embodiments enable recovery with a robotic vehicle of an item placed by a user in a delivery area. The presence of the item in the delivery area may be determined using images captured by a camera, with descriptive recovery parameters derived and included in a recovery request. Recovery parameters may also include information stored in a user account and information input by a user using an application executing on a user device. The delivery area and application may be associated with the user account. The recovery request may be sent to a remote server which dispatches a robotic vehicle to the delivery area to recover the item and routes the robotic vehicle with the recovered item to a location based on information in the user account. A selection of robotic vehicle type may be based on the item's weight or one or more of its physical dimensions.Type: ApplicationFiled: June 13, 2018Publication date: October 3, 2019Inventors: Dylan Scott MATHIAS, Michael Franco TAVEIRA, Charles Paul MATHIAS, Damir DIDJUSTO
-
Publication number: 20190303860Abstract: Various embodiments enable recovery with a robotic vehicle of an item placed by a user on a delivery pad. The presence of the item on the delivery pad may be sensed and various descriptive recovery parameters may be included in a recovery request. Recovery parameters may be derived from measurements acquired at the delivery pad, information stored in the user account, and information input by a user using an application executing on a user device. The application may be associated with the user account. The recovery request may be sent to a remote server which in turn dispatches a robotic vehicle to the delivery pad site to recover the item and routes the robotic vehicle with the recovered item to a location based on information in the user account. A robotic vehicle selection may be based on the item's weight or one or more of its physical dimensions.Type: ApplicationFiled: March 29, 2018Publication date: October 3, 2019Inventors: Dylan Scott MATHIAS, Michael Franco TAVEIRA, Charles Paul MATHIAS, Damir DIDJUSTO
-
Publication number: 20190292157Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: April 10, 2019Publication date: September 26, 2019Applicant: Pfizer Inc.Inventors: Agustin Casimiro-Garcia, Jeffrey Scott Condon, Andrew Christopher Flick, Ariamala Gopalsamy, Steven J. Kirincich, John Paul Mathias, Joseph Walter Strohbach, Jason Shaoyun Xiang, Li Huang Xing, Xiaolun Wang
-
Publication number: 20190270751Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: May 14, 2019Publication date: September 5, 2019Applicant: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Patent number: 10377762Abstract: The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: GrantFiled: September 17, 2018Date of Patent: August 13, 2019Assignee: CYSTIC FIBROSIS FOUNDATIONInventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Ivan Viktorovich Efremov
-
Publication number: 20190225621Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: April 5, 2019Publication date: July 25, 2019Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Krim Gavrin, Ivan Viktorovich Efremov
-
Patent number: 10329302Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: January 5, 2018Date of Patent: June 25, 2019Assignee: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Patent number: 10316018Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: November 30, 2018Date of Patent: June 11, 2019Assignee: Pfizer Inc.Inventors: Katherine Lin Lee, Christophe Philippe Allais, Christoph Martin Dehnhardt, Lori Krim Gavrin, Seungil Han, David Hepworth, Arthur Lee, Frank Eldridge Lovering, John Paul Mathias, Dafydd Rhys Owen, Nikolaos Papaioannou, Eddine Saiah, Joseph Walter Strohbach, John David Trzupek, Stephen Wayne Wright, Christoph Wolfgang Zapf
-
Patent number: 10308615Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: May 16, 2016Date of Patent: June 4, 2019Assignee: Pfizer Inc.Inventors: Agustin Casimiro-Garcia, Jeffrey Scott Condon, Andrew Christopher Flick, Ariamala Gopalsamy, Steven J. Kirincich, John Paul Mathias, Joseph Walter Strobach, Jason Shaoyun Xiang, Li Huang Xing, Xiaolun Wang